<DOC>
	<DOCNO>NCT00947882</DOCNO>
	<brief_summary>A dose-finding , multi-centre , double-blind , randomise , parallel , placebo-controlled trial investigate efficacy safety degarelix men low urinary tract symptom ( LUTS ) associate benign prostatic hyperplasia ( BPH )</brief_summary>
	<brief_title>A Trial Degarelix Men With Lower Urinary Tract Symptoms ( LUTS ) Associated With Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Signed informed consent obtain trialrelated activity perform Men , age 50 old Clinical sign symptom BPH ≥6 month Moderate severe LUTS screening , define International Prostate Symptom Score ( IPSS ) ≥13 An IPSS QoL score ≥3 screen Prostate specific antigen ( PSA ) screen ≤10 ng/mL ( responsibility Investigator rule prostate cancer PSA &gt; 4 ng/mL , except USA patient PSA &gt; 4 ≤10 ng/mL undergo prostatic biopsy negative prostatic biopsy within 12 month prior participation trial ) Maximum urinary flow ( Qmax ) range 5 15 mL/second minimum void volume &gt; 125 mL screen Post void residual volume ( PVR ) &gt; 250 mL Stone bladder urethra cause symptom Acute chronic prostatitis Interstitial cystitis / painful bladder syndrome Acute recurrent urinary tract infection History acute urinary retention ( AUR ) Lower urinary tract instrumentation ( include prostate biopsy ) within 30 day dose Visit 2 Clinical evidence follow urinary tract condition : 1 . Mullerian duct cysts 2 . Atonic , decompensated , hypocontractile bladder 3 . Detrusorsphincter dyssynergia ( contraction detrusor without sphincter relaxation ) History follow pelvic condition : 1 . Pelvic surgery pelvic procedure , include radical prostatectomy , pelvic surgery removal malignancy , open low colonic rectal surgery 2 . Pelvic radiotherapy 3 . Any prior surgical procedure urinary tract , include minimally invasive LUTS/BPH therapy 4 . Lower tract malignancy trauma Clinically significant microscopic haematuria screen History significant renal insufficiency , define receive renal dialysis estimate creatinine clearance &lt; 30 mL/minute screen Systolic blood pressure &gt; 180 &lt; 90 mmHg diastolic blood pressure &gt; 110 &lt; 50 mmHg screen malignant hypertension Any cause BPH , may affect evaluation symptom urine flow ( e.g . neurogenic bladder , bladder neck contracture , urethral stricture , bladder malignancy ) judge Investigator Use prohibit therapy Elevated liver function test screen : 1 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) &gt; 2 time upper limit normal 2 . Total bilirubin &gt; 1.5 time upper limit normal QTc interval screen ECG &gt; 450 m , family history long QT syndrome Any clinically significant disorder ( BPH ) include , limited , renal , haematological , gastrointestinal , endocrine , cardiac , neurological , psychiatric disease , condition , may affect patient 's health outcome trial judge Investigator Diagnosed cancer within last 5 year except adequately manage basal cell carcinoma squamous cell carcinoma skin History severe untreated asthma , anaphylactic reaction , severe urticaria and/or angioedema Mental incapacity language barrier preclude adequate understanding cooperation History current evidence drug , alcohol , substance abuse within 6 month prior screen Hypersensitivity towards component investigational medicinal product ( IMP ) Previous participation degarelix trial</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>